The management model of long-acting antibody (LAAB) in Nakhon Ratchasima Province

Main Article Content

Kaitsuda Saiprom
Taweechai Wisanuyothin
Doungjun Chanmaung
Wiwat Sungkabut

Abstract

According to the policy of Ministry of Public Health, it was recommended to used Long-acting antibody (LAAB) in populations with compromised immunization or those not responding to vaccination to improved immunization for prevention diseases. However, the implementation of LAAB did not achieve its goal in these populations. Consequently, the Ministry of Public Health released strategies to enhance access to LAAB, including providing information and communication to doctors, healthcare workers and target populations. Additionally, opportunities were increased for target populations to receive information and make decisions (Encouraging Decision) in elderly care facilities. It was followed by an increase in the “intent to inject after receiving information” (Opt-out strategy) among target populations to decide on the injection of LAAB. Area Health 9 start these strategies in Nakhon Ratchasima province by cooperated with public health partner and local administrative organization. Office of Disease Prevention and Control, Region 9 Nakhon Ratchasima cooperated with Office of Disease Prevention and Control, Region 4 Saraburi, to initiate the strategies in 4 districts of Nakhon Ratchasima province including Soeng Sang, Khon Buri, Pak Thong Chai and Chokchai, during 17 July to 22 August 2023. The total number of individuals requiring LAAB injection was 8,492 persons, and the decision to receive LAAB was made by 7,592 persons (96.52%) out of 7,800 persons in the target populations. Three important procedures were utilized, including a service model in health centers, logistics model for efficient transportation of LAAB and a reporting systems model.

Article Details

How to Cite
1.
Saiprom K, Wisanuyothin T, Chanmaung D, Sungkabut W. The management model of long-acting antibody (LAAB) in Nakhon Ratchasima Province. JMPH4 [internet]. 2025 Mar. 14 [cited 2025 Mar. 17];15(1):108-15. available from: https://he01.tci-thaijo.org/index.php/JMPH4/article/view/266653
Section
Original Articles

References

Department of Disease Control (TH). Guideline for administer long-acting antibody in Thailand 2022 [Internet]. Nonthaburi: Department of Disease Control; 2022 [cited 2023 Sep 8]. Available from: https://ddc.moph.go.th/vaccine-covid19/getFiles/ 11/1669968711550.pdf

Royal College of Physicians of Thailand. Practice guidelines for administering the COVID-19 vaccine to adults and medical patients 2021. Bangkok: Royal College of Physicians of Thailand; 2021[cited 2023 Sep 10]. Available from: https://ddc.moph.go.th /vaccine-covid19/getFiles/ 13/1622091631926.pdf

The Ministry of Public Health and Medical Association of Thailand. Recommendations for Long-acting antibody (LAAB) of pre-exposure prevention and treatment of COVID-19 (March 2023) [Internet]. Bangkok; The Ministry of Public Health and Medical Association of Thailand; 2023 [cite 2023 Sep 15]. Available from: https://ddc.moph.go.th/uploads/ publish/1402820230322130408.pdf

Department of Disease Control (TH). Guideline for administer long-acting antibody in Thailand, revised version 2 [Internet]. Nonthaburi: Department of Disease Control; 2023 [cited 2023 Sep 22]. Available from: https://ddc.moph.go.th/vaccine-covid19/getFiles/11/1669968744374.pdf